EGFR and neoplasm: This may be attributed to EGFR’s low-level expression in normal tissues, which constrains dosing due to on-target/off-tumor risks, and to the immunosuppressive TME, including PD-L1 expression and T-cell exhaustion, which limit CAR-T expansion and activity.